A phase II clinical trial evaluating a personalized cancer vaccine, AV-GBM-1, in patients with newly diagnosed glioblastoma, demonstrated a 42% reduction in risk of disease progression or death at 6.9 months.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe